http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 29 Jul 2026 08:01:09 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+adds+Baylor+site+to+lymphoma+trial/26830948.html <p>Estrella Immunopharma, Inc. (NASDAQ: ESLA) has activated Baylor Scott & White Research Institute in Dallas, Texas, as a second clinical site for its STARLIGHT-1 Phase I/II trial evaluating EB103, a CD19-directed T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).</p><p>According to a press release, the Dallas site has begun screening and enrolling patients. The trial's first site, UC Davis Comprehensive Cancer Center, remains active. The study is registered at clinicaltrials.gov under NCT06343311.</p><p>The expansion phase of the trial is a multi-center, open-label study evaluating the safety and efficacy of EB103 at the recommended Phase II dose in patients http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+adds+Baylor+site+to+lymphoma+trial/26830948.html Wed, 29 Jul 2026 08:01:09 -0400 ESLA http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (“R/R”) B-cell non-Hodgkin’s lymphoma (“NHL”). The new site, Baylor Research Institute d/b/a Baylor Scott &amp; White Research Institute in Dallas, Texas, has begun screening and enrolling patients.</p><p>“Partnering with Baylor Scott &amp; White Research Institute, a nationally recognized http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Activates+Baylor+Scott+%26amp%3B+White+Research+Institute+as+Second+Clinical+Site+for+Phase+III+STARLIGHT-1+Trial+in+B-cell+Non-Hodgkin%E2%80%99s+Lymphoma/26830864.html Wed, 29 Jul 2026 08:00:00 -0400 A.22832583 A.50214643 ESLA O.10291238 O.35847762 O.52433315 http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+doses+first+patient+in+EB103+expansion+trial/26810875.html <p>Estrella Immunopharma, Inc. (NASDAQ: ESLA) announced that the first patient has been dosed in the dose-expansion phase of its STARLIGHT-1 Phase I/II clinical trial, which is evaluating EB103, a CD19-redirected T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).</p><p>The expansion phase follows data from the dose-escalation cohort showing that, at a six-month assessment of evaluable Phase I patients without central nervous system involvement, all patients who achieved a complete response remained in complete response.</p><p>"This marks an important milestone for Estrella and STARLIGHT-1," said Cheng Liu, PhD, Chief Executive Officer of Estrella. "The sustained complete responses observed to http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+doses+first+patient+in+EB103+expansion+trial/26810875.html Fri, 24 Jul 2026 08:00:35 -0400 ESLA http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). </p><p> Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients with no CNS involvement, http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Announces+First+Patient+Dosed+in+Dose-Expansion+Phase+of+STARLIGHT-1+Trial+and+Reports+Durable+Response+Rate+in+Advanced+B-Cell+Non-Hodgkin%E2%80%99s+Lymphoma/26810847.html Fri, 24 Jul 2026 08:00:00 -0400 A.50214643 ESLA O.35847762 O.52433315 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26714992.html si-local-file:///var/storage/secattach/20260630/26714992.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26714992.html Tue, 30 Jun 2026 17:30:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26714992.html si-local-file:///var/storage/secattach/20260630/26714992.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26714992.html Tue, 30 Jun 2026 17:30:00 -0400 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26559212.html si-local-file:///var/storage/secattach/20260527/26559212.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Estrella+Immunopharma%2C++++For%3A+Jun+29/26559212.html Wed, 27 May 2026 17:26:00 -0400 ESLA O.52433315